cbdMD Achieves Strong Revenue Growth, Prepared for Hemp CBD Integration into Medicare

cbdMD Reports Strong Growth and Future Prospects

cbdMD, Inc. recently announced significant financial results for Q2 of fiscal year 2026, showcasing a remarkable growth of 19% year-over-year and 12% sequentially. This achievement comes from both the core business's consistent performance and the contributions of newly acquired Bluebird Botanicals, a respected name in the CBD industry.

According to Ronan Kennedy, CEO and CFO of cbdMD, the company managed to execute well across various fronts during this quarter. The revenue generated, excluding that from the Bluebird acquisition, hit a peak not witnessed since the first fiscal quarter of 2023. Kennedy emphasized how the strategic integration of Bluebird Botanicals sets an exemplary template for further acquisition opportunities in the hemp and health sectors.

As cbdMD navigates the evolving regulatory landscape, recent legislative developments have opened doors for operators in the cannabis domain. Notably, the Center for Medicare & Medicaid Services (CMS) introduced the BEI Medicare pathway on April 1, enabling certain participants to supply hemp-derived products to beneficiaries. This initiative allows approved organizations to provide up to $500 annually in non-intoxicating CBD products which align with the ongoing shifts in policies toward cannabis.

Key Business Updates

Successful Integration of Bluebird Botanicals

The completion of the Bluebird Botanicals acquisition in January 2026 marks a pivotal moment for cbdMD. Despite initial earnings impacts due to transition costs, Bluebird is set to generate positive income this March, with early Q3 revenues trending upwards. Management anticipates that as additional products become available and operational efficiencies are realized, Bluebird will significantly contribute to both revenue and earnings.

Activation of BEI Medicare Pathway

With the recent activation of the BEI Medicare program, cbdMD is well-positioned as a preferred supplier of evidence-based CBD products. The company has launched a dedicated clinical healthcare channel aimed at engaging Accountable Care Organizations (ACOs) and health systems, bolstering its presence as regulatory clarity evolves. This strategic positioning highlights cbdMD's commitment to complying with high-quality safety standards and developing strong clinical evidence.

Legislative Momentum

In addition to its operational endeavors, cbdMD is keenly tracking bipartisan efforts in Congress aimed at amending restrictive hemp legislation from late 2025. As the regulatory environment continues to shift towards clearer frameworks, cbdMD anticipates a favorable landscape for compliant and capitalized operators maintaining rigorous quality and safety standards.

Financial Highlights

In fiscal 2026, cbdMD reported net sales of $5.6 million, a notable increase from $4.7 million in the previous year. However, the company faced a loss from operations totaling $801,000, which increased from $485,000 year-over-year. Adjusted EBITDA loss also surged slightly to approximately $220,000, indicating ongoing investment into growth initiatives despite operating losses.

As of March 31, 2026, cbdMD held approximately $2.6 million in cash and a working capital of roughly $5.4 million, demonstrating a robust liquidity position compared to $2.2 million cash and $3.3 million in working capital the previous September.

Moreover, direct-to-consumer (DTC) sales accounted for 67% of total sales, showcasing a shift towards enhanced customer engagement, with wholesale sales increasing significantly from the prior year.

Looking Ahead

As cbdMD gears up for its upcoming conference call, the company plans to deepen discussions around its recent achievements and strategic plans for long-term growth. With the ongoing integration of Bluebird Botanicals and the potential of the Medicare BEI pathway, cbdMD is walking a promising path towards sustainable growth in the highly competitive CBD market. The future seems optimistic for cbdMD as legislative clarity continues to support the burgeoning hemp and wellness industries.